MedElevator Войти в исследования
← Поиск публикаций

DOI 10.11406/rinketsu.65.622

Медицинская библиотека · [Rinsho ketsueki] The Japanese journal of clinical hematology · 2024

[Relapsed primary central nervous system lymphoma treated with CD19 chimeric antigen receptor T-cell therapy and allogeneic hematopoietic stem cell transplantation].

Fujii Fuminari, Terao Toshiki, Nishimori Hisakazu, Fujii Kentaro, Matsuo Toshihiko, Yoshino Tadashi, Ueda Hiroko, Oyama Tadashi, Matsumura Akifumi, Kondo Kaho, Matsubara Chisato, Fujiwara Kanako, Seike Keisuke, Fujiwara Hideaki, Asada Noboru, Ennishi Daisuke, Fujii Keiko, Fujii Nobuharu, Matsuoka Ken-Ichi, Maeda Yoshinobu

СтатьяКлинический случайАннотация на английскомПеревод в очереди

Аннотация

Relapsed and/or refractory (R/R) primary central nervous system lymphoma (PCNSL) has a poor prognosis. A 57-year-old man diagnosed with PCNSL achieved a complete response by high-dose methotrexate-based chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT). The disease was not cured, so he was treated with the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel after the third relapse. However, the disease relapsed again 28 days after CAR T-cell therapy. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) was attempted as curative therapy after bridging with second ASCT and tirabrutinib monotherapy. Although a temporary response was achieved, the disease relapsed 98 days after allo-HSCT. While receiving tirabrutinib for relapse after allo-HSCT, the patient developed acute respiratory failure due to transplant-related toxicity and post-transplant thrombotic microangiopathy. He died 175 days after allo-HSCT. Although various treatments for PCNSL have been investigated in recent years, the treatment strategy for R/R PCNSL has not been established. Further studies are warranted to improve the outcomes of patients with R/R PCNSL.

Для цитирования: Fujii Fuminari, Terao Toshiki, Nishimori Hisakazu, Fujii Kentaro, Matsuo Toshihiko, Yoshino Tadashi, Ueda Hiroko, Oyama Tadashi, Matsumura Akifumi, Kondo Kaho, Matsubara Chisato, Fujiwara Kanako, Seike Keisuke, Fujiwara Hideaki, Asada Noboru, Ennishi Daisuke, Fujii Keiko, Fujii Nobuharu, Matsuoka Ken-Ichi, Maeda Yoshinobu. [Relapsed primary central nervous system lymphoma treated with CD19 chimeric antigen receptor T-cell therapy and allogeneic hematopoietic stem cell transplantation].. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2024. DOI: 10.11406/rinketsu.65.622.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.